首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Multicenter Evaluation of MIC Distributions for Epidemiologic Cutoff Value Definition To Detect Amphotericin B Posaconazole and Itraconazole Resistance among the Most Clinically Relevant Species of Mucorales
【2h】

Multicenter Evaluation of MIC Distributions for Epidemiologic Cutoff Value Definition To Detect Amphotericin B Posaconazole and Itraconazole Resistance among the Most Clinically Relevant Species of Mucorales

机译:多中心评估流行病学截止值定义的MIC分布以检测临床上最相关的毛霉菌对两性霉素B泊沙康唑和伊曲康唑的耐药性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Clinical breakpoints (CBPs) have not been established for the Mucorales and any antifungal agent. In lieu of CBPs, epidemiologic cutoff values (ECVs) are proposed for amphotericin B, posaconazole, and itraconazole and four Mucorales species. Wild-type (WT) MIC distributions (organisms in a species-drug combination with no detectable acquired resistance mechanisms) were defined with available pooled CLSI MICs from 14 laboratories (Argentina, Australia, Canada, Europe, India, Mexico, and the United States) as follows: 10 Apophysomyces variabilis, 32 Cunninghamella bertholletiae, 136 Lichtheimia corymbifera, 10 Mucor indicus, 123 M. circinelloides, 19 M. ramosissimus, 349 Rhizopus arrhizus, 146 R. microsporus, 33 Rhizomucor pusillus, and 36 Syncephalastrum racemosum isolates. CLSI broth microdilution MICs were aggregated for the analyses. ECVs comprising ≥95% and ≥97.5% of the modeled populations were as follows: amphotericin B ECVs for L. corymbifera were 1 and 2 μg/ml, those for M. circinelloides were 1 and 2 μg/ml, those for R. arrhizus were 2 and 4 μg/ml, and those for R. microsporus were 2 and 2 μg/ml, respectively; posaconazole ECVs for L. corymbifera were 1 and 2, those for M. circinelloides were 4 and 4, those for R. arrhizus were 1 and 2, and those for R. microsporus were 1 and 2, respectively; both itraconazole ECVs for R. arrhizus were 2 μg/ml. ECVs may aid in detecting emerging resistance or isolates with reduced susceptibility (non-WT MICs) to the agents evaluated.
机译:尚未确定Mucorales和任何抗真菌药的临床断点(CBP)。代替CBP,提出了针对两性霉素B,泊沙康唑和伊曲康唑以及4种毛霉菌的流行病学临界值(ECV)。使用来自14个实验室(阿根廷,澳大利亚,加拿大,欧洲,印度,墨西哥和美国)的可用合并CLSI MIC定义了野生型(WT)MIC分布(物种-药物组合中的生物,没有可检测到的获得性耐药机制) )如下:10个变种拟杆体,32个坎宁哈姆氏菌,136个立克次氏菌,10个印度,、 123 M circinelloides,19 M. ramosissimus,349个阿育根根霉,146个小孢子孢子,33个根瘤菌和33个根瘤菌。将CLSI肉汤微稀释MIC进行汇总以进行分析。组成≥95%和≥97.5%的模拟人群的ECV如下:两性霉素B ry虫的ECV分别为1和2μg/ ml,圆环疟原虫的ECV分别为1和2μg/ ml,小rrh根除草剂的ECV为1和2μg/ ml。分别为2和4μg/ ml,而小孢子虫的分别为2和2μg/ ml;泊沙康唑ECV用于 L。 corymbifera 是1和2,是 M。 circinelloides 是4和4,用于 R。 Arrhizus 为1和2,而 R。小孢子虫分别为1和2;这两个伊曲康唑ECV均属于 R。没药为2μg/ ml。 ECV可能有助于检测新出现的耐药性或对评估的药物敏感性降低的分离株(非WT MIC)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号